Race to Own Clinician Workflow
OpenEvidence vs. ChatGPT for Clinicians
This launch means clinician AI is shifting from a vertical app battle into a distribution battle, because OpenAI can turn an already familiar general tool into a free doctor specific workflow. OpenAI entered in stages, first with ChatGPT Health for consumers in January 2026, then ChatGPT for Healthcare for health systems, then ChatGPT for Clinicians in April 2026 with documentation support and public healthcare data access for verified U.S. clinicians.
-
OpenEvidence built its wedge by giving doctors fast evidence search without touching patient records, which made bottom up adoption possible in a market where PHI usually forces long enterprise sales cycles. That same self serve motion is exactly what makes it vulnerable to a free product inside ChatGPT.
-
The product surface is converging across players. ChatGPT for Clinicians helps draft notes, referrals, prior authorization letters, and patient instructions. OpenEvidence has already expanded from search into scribing, coding suggestions, calling, and prescription workflows. Abridge is also moving from ambient notes into coding and clinical decision support.
-
OpenAI brings unusual reach. ChatGPT passed 1 billion weekly active users by July 2026, and OpenAI’s health tools were built on evidence that millions were already using ChatGPT for health questions. That lowers the activation cost for doctors who were already experimenting with ChatGPT off platform.
The next step is a race to own the doctor’s full working screen. General models can win quick adoption with free research and drafting, but the durable winners will be the products that plug into records, capture the live visit, and turn one clinician question into notes, codes, orders, and follow up actions inside the care workflow.